Janux Therapeutics (JANX) Receivables - Net (2020 - 2024)
Janux Therapeutics (JANX) has disclosed Receivables - Net for 5 consecutive years, with $7.5 million as the latest value for Q2 2024.
- Quarterly Receivables - Net changed N/A to $7.5 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Jun 2024, changed N/A year-over-year, with the annual reading at $8.0 million for FY2020, N/A changed from the prior year.
- Receivables - Net for Q2 2024 was $7.5 million at Janux Therapeutics, up from $519000.0 in the prior quarter.
- The five-year high for Receivables - Net was $8.0 million in Q4 2020, with the low at $400000.0 in Q2 2021.
- Average Receivables - Net over 5 years is $3.0 million, with a median of $659500.0 recorded in 2023.
- Peak annual rise in Receivables - Net hit 35.12% in 2024, while the deepest fall reached 35.12% in 2024.
- Over 5 years, Receivables - Net stood at $8.0 million in 2020, then crashed by 95.0% to $400000.0 in 2021, then grew by 25.0% to $500000.0 in 2022, then skyrocketed by 60.0% to $800000.0 in 2023, then skyrocketed by 837.5% to $7.5 million in 2024.
- According to Business Quant data, Receivables - Net over the past three periods came in at $7.5 million, $519000.0, and $800000.0 for Q2 2024, Q1 2024, and Q1 2023 respectively.